

# Information for Connecticut Prescribers of Prescription Drugs

## Kisunla® (donanemab-azbt)

- Connecticut Public Act No. 23-171 requires “pharmaceutical representatives” (as defined in the Act) provide certain information to prescribers and pharmacists. The information in this disclosure is being provided pursuant to this Act.
- Lilly USA, LLC's Wholesale Acquisition Cost (WAC) is the listed price to the distribution channel not including prompt pay, service or administrative fees, stocking or distribution allowances, or any discounts, rebates, or chargebacks provided by Lilly USA to any entity.

### **Product:**

BRAND NAME	GENERIC NAME	STRENGTH	DOSAGE FORM	PACK SIZE	NDC	WHOLESALE ACQUISITION COST <sup>1</sup>
Kisunla®	donanemab-azbt	350 mg/20 mL	Single-dose Vial	1 vial	0002-9401-01	\$717.79

Limited data exists on KISUNLA efficacy based on race and ethnicity, and no conclusions can be made on whether the effectiveness seen in the trial population would be different in patients of different races or ethnicity.<sup>2</sup>

Please see full [Prescribing Information](#), including Boxed Warning regarding ARIA, and [Medication Guide](#) for Kisunla.

Kisunla® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates. Other product/company names mentioned herein are the trademarks of their respective owners.

This information is intended for US Healthcare Providers only.

<sup>1</sup> Source: AnalySource®. Accessed on 04/02/2026. WAC reprinted with permission by First Databank Inc. All rights reserved. © 2026. <http://www.fdbhealth.com/policies/drug-pricing-policy/>.

<sup>2</sup> Kisunla (donanemab-azbt). Prescribing Information. Lilly USA, LLC.